Cardiol Therapeutics (TSE:CRDL)
TSX:CRDL
CRDL Stock Chart & Stats
C$1.40
-C$0.08(-4.06%)
At close: 4:00 PM EST
C$1.40
-C$0.08(-4.06%)
Day’s Range― - ―
52-Week RangeC$1.09 - C$2.17
Previous CloseN/A
Volume34.34K
Average Volume (3M)136.50K
Market Cap
C$216.66M
Enterprise ValueC$205.17M
Total Cash (Recent Filing)C$11.62M
Total Debt (Recent Filing)C$134.20K
Price to Earnings (P/E)―
Beta2.27
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding111,680,084
10 Day Avg. Volume86,077
30 Day Avg. Volume136,495
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)5.35
Price to Sales (P/S)0.00
P/FCF Ratio-5.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$11.84Price Target Upside745.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cardiac Remodeling SignalObserved reductions in left ventricular mass and favorable trends across myocardial structure measures suggest the therapy could reverse harmful remodeling and bolster the case for the subcutaneous CRD-38 heart failure program.
Clinical Trial ProgressOngoing Phase III MAVERIC enrollment progress combined with Phase II evidence of pain, inflammation, and recurrence reductions supports potential near-term value uplift as additional patient data are reported.
Peer-reviewed ValidationPeer-reviewed ARCHER publication confirming the drug's anti-inflammatory effect in humans enhances scientific credibility and may ease regulatory and partner discussions.
Bears Say
Imaging Quality And Analyzable SampleImaging limitations that reduced the number of analyzable patients raise concerns about data completeness and the robustness of some trial conclusions.
Regulatory And Partnership RiskUncertainty stemming from imaging and power issues could complicate regulatory interpretation and slow partner interest or deal negotiations for the program.
Statistical Power And Endpoint UncertaintySmaller analyzable samples for key measurements likely left the primary endpoint underpowered, creating uncertainty around formal statistical significance.
Cardiol Therapeutics News
CRDL FAQ
What was Cardiol Therapeutics’s price range in the past 12 months?
Cardiol Therapeutics lowest stock price was C$1.09 and its highest was C$2.17 in the past 12 months.
What is Cardiol Therapeutics’s market cap?
Cardiol Therapeutics’s market cap is C$216.66M.
When is Cardiol Therapeutics’s upcoming earnings report date?
Cardiol Therapeutics’s upcoming earnings report date is May 19, 2026 which is in 42 days.
How were Cardiol Therapeutics’s earnings last quarter?
Cardiol Therapeutics released its earnings results on Mar 31, 2026. The company reported -C$0.07 earnings per share for the quarter, beating the consensus estimate of -C$0.09 by C$0.02.
Is Cardiol Therapeutics overvalued?
According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued.
Does Cardiol Therapeutics pay dividends?
Cardiol Therapeutics does not currently pay dividends.
What is Cardiol Therapeutics’s EPS estimate?
Cardiol Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cardiol Therapeutics have?
Cardiol Therapeutics has 111,680,084 shares outstanding.
What happened to Cardiol Therapeutics’s price movement after its last earnings report?
Cardiol Therapeutics reported an EPS of -C$0.07 in its last earnings report, beating expectations of -C$0.09. Following the earnings report the stock price went up 3.175%.
Which hedge fund is a major shareholder of Cardiol Therapeutics?
Currently, no hedge funds are holding shares in TSE:CRDL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiol Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$11.84 (745.56% Upside)
C$11.84 (745.56% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.03%
12-Months-Change
Fundamentals
Return on Equity
-218.48%
Trailing 12-Months
Asset Growth
-22.22%
Trailing 12-Months
Company Description
Cardiol Therapeutics
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
CRDL Stock 12 Month Forecast
Average Price Target
C$11.84
▲(745.56% Upside)
Technical Analysis
Bausch Health Companies
―
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Medicure
―
Medexus Pharmaceuticals Inc
―
Options Prices
Currently, No data available
---